Clinical Trial Detail

NCT ID NCT02635061
Title Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Acetylon Pharmaceuticals Incorporated
Indications

lung non-small cell carcinoma

Therapies

Citarinostat + Ipilimumab + Nivolumab

Age Groups: adult

No variant requirements are available.